Meridia labeling
Executive Summary
Abbott met with FDA Chief Counsel Daniel Troy July 11 to discuss labeling issues for Meridia (sibutramine). Public Citizen's petition requesting withdrawal of the obesity agent has been pending at FDA since March 2002 (1"The Pink Sheet" March 25, 2002, p. 21)...